Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus Durvalumab in Advanced GI or Thoracic Malignancies
NCT02572687Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 8
01
Overview
Phase 1, open-label trial of ramucirumab and durvalumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with Dose Limiting Toxicities. Started Feb 2016; status: completed.
02
Drugs
ramucirumabdurvalumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02572687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572687.